More on Keryx Biopharmaceutical (KERX): Q1 misses on a per share basis due to higher R&D...

|About: Keryx Biopharmaceuticals, Inc. (KERX)|By:, SA News Editor

More on Keryx Biopharmaceutical (KERX): Q1 misses on a per share basis due to higher R&D expenses, due principally to its KRX-0401 and Zerenex Phase 3 clinical programs. Shares -0.7% AH.